C. PHILIP O'CARROLL, M.D. | | Diplomate, American Board of Neurology | | Clinical Neurology & Electromyography | Diplomate, American Board of Psychiatry | | Medical Director, Newport Pain Treatment Center |
CURRICULUM VITAE
EDUCATION
University College Dublin Medical School - 1968 to 1975 (combined College & Medical School) RESIDENCIES
Internal Medicine: University Alberta Hospital, Edmonton, Canada 1975 to 1978
Neurology: Massachusetts General Hospital, Boston, Massachusetts 1978 - 1981 FELLOWSHIP
Clinical Electrophysiology, Mayo Clinic, Rochester, Minnesota LICENSURE
California & Massachusetts
CERTIFICATION
American Board of Psychiatry & Neurology, 1986 American Board of Internal Medicine, 1980
American Board of Psychiatry & Neurology, Subspecialty in Pain Management, 2002
PROFESSIONAL EXPERIENCE 1982 to Present: | Private Practice in Newport Beach, California
| 1988: | Founded The Headache & Pain Institute specializing in the treatment of intractable headache problems. The Institute consists of neurologist, psychiatrist, behavioral psychologist, marital therapist, physical therapist and anesthesiologist. Over 9,000 patients treated.
| 1990: | Founded pain service at Hoag Memorial Presbyterian Hospital, Newport Beach, California.
| 1990 - 1994: | Co-Director, Chronic Pain Program, College Hospital, Costa Mesa, California
| 1994 - Present: | Director, Newport Pain Treatment Center, Newport Beach, California | AFFILIATIONS
American Assoc. For the Study of Headache American Headache Society American Pain Society American Academy of Neurology National Headache Foundation International Assoc. For the Study of Pain Orange County Medical Association HOSPITAL AFFILIATION Hoag Memorial Presbyterian Hospital, Newport Beach, California
BIBLIOGRAPHY
Kohlmeir-Degos' Disease, NEJM, 1980
Cerebral Aspergillosis, Neurology, 1981 Mushroom Sign in Malignant Meningiomas, Journal of CT Scanning, 1981 The Syndrome of Spontaneous Intracranial Hypotension, 1998 (In print) Migraine, Serotonin, and the Mind-Body Dilemma, Economics of Neuroscience, Mar 2001 RESEARCH EXPERIENCE 1989: | GLAXO Protocol No. S2B-305: "A Multi-Center Evaluation of the Safety and Efficacy of Subcutaneous GR43175C in Patients with Acute Migraine Attacks Using a Two-Dose Regimen" | 1992: | SANDOZ, Medication Study of IM DHE-45 in the treatment of migraine | 1993: | SANDOZ Study No. E-301: "A Double-Blind, Controlled, Multi-Center Study to Assess the Efficacy and Safety of D.H.E. 45 (Dihydroergotamine Mesylate) Nasal Spray 2.0 mg and 3.0 mg Doses in Comparison with Placebo for the Acute Treatment of Migraine Headache" | 1993/94 | GLAXO Protocol No. S2B-351: "A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sumatriptan Suppositories in the Acute Treatment of a Single Migraine Attack" | 1994: | GLAXO Protocol S2B-342: "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Headache Pain Relief with Sumatriptan Nasal Spray (5 mg., 10mg., and 20 mg.) Across Three Migraine Attacks" | 1995: | SANDOZ Study No. DHE 454: "A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effectiveness and Safety of Dihydroergotamine Mesylate Nasal spray 2 mg for the Acute Treatment of Migraine Headache With or Without Aura in Migraineur Families" | 1993/95: | GLAXO Protocol S2B-350: "Imitrex Post Marketing Surveillance Study" Sumatriptan injection | 1997: | QUINTILES VML 251/96/07: "A Double-Blind, Placebo-Controlled, Parallel - Group Study to Assess the Efficacy and Safety of Up to Two Doses of VML251 in the Acute Treatment of Migraine"
QUINTILES Protocol No. 160-103: "A Multicenter, Double-Blind, Randomized Placebo-Controlled, Parallel Group Study Of The Efficacy And Safety Of Escalating The Dose Of Oral Eletriptan In Subjects With Acute Migraine"
QUINTILES Protocol No. 160-108: "A Multicenter, Randomized, Open Label, Comparative Study Of The Safety, Toleration And Efficacy Of Oral Eletriptan For Long Term Treatment Of Subjects With Acute Migraine". | 1999: | ASTRAZENECA Protocol No. 311CUS/0003:"A Multicenter, 2 Phase Double-blind, Randomized, Placebo-Controlled, Parallel Trial to Evaluate the Efficacy of Repeated Oral Doses of Zolmitriptan as Prophylactic Treatment for Menstrual Migraine Headaches".
GlaxoSmithKline Protocol No. S2W40012/S2W40024: "A Randomized, Double-blind, Placebo-Controlled Parallel Group Evaluation of Oral Naratriptan 1mg Twice Daily as Prophylactic Treatment for Menstrually-Associated Migraine". |
2000 |
POZEN Inc. Protocol No. MT100-304: "A Single Dose, Double-Blind, Safety and Efficacy Study of MT100, Metoclopramide Hydrochloride and Naproxen Sodium in Subjects with Acute Migraine Attacks". | 2000 | ALLERGAN Protocol 191622-036: "A multicenter, double-blind, randomized, placebo-controlled parallel group study of the continuation of benefit of the two doses of BOTOX (botulinum Toxin, Type A) purified neurotoxin complex for the prophylactic treatment of migraine headaches." | 2000 | INC Research/GLAXO Protocol S2W40027: "An open-label evaluation of the long-term safety of oral Naratriptan 1 mg twice daily as short-term prophylactic treatment for menstrually-associated migraine." | 2000-01 | PAREXEL Protocol 311CUS/0003-0017: ?A multicenter, 2-pase, double-blind, randomized, placebo-controlled, parallel trial to evaluate the efficacy of repeated oral doses of Zolmitriptan (ZOMIG®) as prophylactic treatment for MENSTRUAL MIGRAINE HEDACHE. | 2001-03 | ALLERGAN Protocol 191622-039: "A multi-center, double-blind, randomized, placebo-controlled parallel group study of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex for the prophylactic treatment of HEADACHES in the CHRONIC HEADACHE population." | 2002 |
PAREXEL Trial Number: 311CUS/0003: "A Multicenter, 2-phase, Double-blind, Randomized, Placebo- controlled, Parallel Trial to Evaluate the Efficacy of a Single Dose of Solmitriptan (Zomig®) as Acute Treatment in Phase I and Repeated Doses as Preemptive Treatment in Phase II for Menstrual Migraine Headache" |
2002 - 2003 |
Astra- Zeneca Trial Number: 311 CUS/00022: "A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG®) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine." | Dec 2003 to Feb 2004: | GlaxoSmithKline: Protocol# SUM30047: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumitriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine. | Dec 2003 to Present: | GlaxoSmithKline: Protocol# NPP30010: A Multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of lamotrigine in subjects with neuropathic pain and inadequate pain relief with gabapentin, tricyclic antidepressants or non-narcotic analgesics. | Dec 2003 to Mar 2004: | Merck & Co.,Inc.: Protocol# MTEP(Migraine Therapy Evaluation Protocol) : A Multicenter, Open-Label, Crossover Study Comparing MaxaltÒ (Rizatripatan Benzoate) With Usual Care Oral Migarine Medications |
Feb 2004 to June 2004: |
Bertek Pharmaceuticals Inc.(clinical study managed by PPD-CRO)Protocol# "IMPACT(Implications of Motor Fluctuations in Parkinson?s Patients on Chronic Therapy) Registry." | Apr 2004 to Present: | GlaxoSmithKline: Protocol#101468/228: Onset of Motor Complications | Apr 2004 to Present: | GlaxoSmithKline: Protocol#LAM40124: An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy. | July 2004 to Present: | Ligand Pharmaceuticals: Protocol#PIND#101: AVINZA Pain Relief Study(Pain Control and Improved Functioning in Patients with Chronic Pain Treated with AVINZA). | TEACHING EXPERIENCE |
| |